Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cell Signaling in Plants01:25

Cell Signaling in Plants

5.7K
Plant cells communicate to coordinate their cycle of growth, flowering and fruiting, and activities in roots, shoots, and leaves in response to the changing environmental conditions. Plant signaling is distinct from animal signaling. Plants primarily utilize enzyme-linked receptors, whereas the largest class of cell-surface receptors in animals are G-protein coupled receptors (GPCRs). Unlike animals, receptor tyrosine kinases are rare in plants. Instead, plants have a diverse class of...
5.7K
GPCR Desensitization01:12

GPCR Desensitization

6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.7K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

12.4K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

<sup>18</sup>F-fluciclovine positron emission tomography uptake is not exclusive to malignant brain tumors: Two cases of low-grade and benign lesions with detailed pathological findings.

Surgical neurology international·2026
Same author

Crystalglobulin-Induced Nephropathy and Cardiac Nonamyloidotic Immunoglobulin Deposition Disease: A Fatal Case Report.

Kidney medicine·2026
Same author

Technical principles of watertight dural closure in endoscopic endonasal surgery: How I do it.

Acta neurochirurgica·2026
Same author

Interactions between atomic-scale skyrmions in 2D chiral magnets.

Scientific reports·2026
Same author

Complete Remission After Percutaneous Renal Artery Angioplasty for Focal Segmental Glomerulosclerosis due to Takayasu Disease: A Case Report.

Kidney medicine·2026
Same author

Observation of the Einstein-de Haas effect in a Bose-Einstein condensate.

Science (New York, N.Y.)·2026

関連する実験動画

Updated: Sep 9, 2025

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

10.6K

[Aβ受容器 PirBとLOTUSによるその規制]

Yuki Kawaguchi1, Kohtaro Takei1

  • 1Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine.

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
|August 31, 2025
PubMed
まとめ
この要約は機械生成です。

研究者は,アルツハイマー病 (AD) 治療のための新しい薬標的を特定しました. ペアリングされた免疫グロブリン型受容体B (PirB) とそのレギュレータLOTUSは,認知機能の改善とADの病変と闘う可能性を示しています.

さらに関連する動画

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
06:19

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model

Published on: October 20, 2023

2.2K

関連する実験動画

Last Updated: Sep 9, 2025

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

10.6K
Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
06:19

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model

Published on: October 20, 2023

2.2K

科学分野:

  • 神経科学
  • 薬理学について
  • 生物化学

背景:

  • アルツハイマー病 (AD) の病因は広く研究されていますが 効果的な治療法はまだ見つかっていません
  • ペアリングされた免疫グロブリン型受容体B (PirB) は,可塑性を調節し,アミロイドβ (Aβ) に反応する神経受容体である.

研究 の 目的:

  • ADの新たな治療目標としてPirBを研究する
  • 皮ルBの内生性阻害体としての横側嗅経路アザー物質 (LOTUS) の役割とAD治療におけるその可能性を調査する.

主な方法:

  • PirB,LOTUS,および神経の可塑性およびAβ病理におけるその役割に関する既存の研究のレビュー.
  • Aβ受容体としてのPirBの機能とそのニューロン健康への影響の分析.

主要な成果:

  • PirBは神経の可塑性の負の調節剤として作用し,その抑制は可塑性,脊椎の密度,および認知機能を高めます.
  • PirBはAβの受容体として機能し,神経毒性と可塑性の低下を媒介する.
  • LOTUSはPirBの内生抗体であり,Aβ誘発の神経毒性を抑制する.

結論:

  • PirBはアルツハイマー病の新薬として有望です
  • LOTUSはPirBのAβ受容体の機能を阻害することで,Aβ病理に対する治療効果がある可能性があります.